| Thrombosis: a major contributor to global disease burden GE Raskob, P Angchaisuksiri, AN Blanco, H Buller, A Gallus, BJ Hunt, ... Arteriosclerosis, thrombosis, and vascular biology 34 (11), 2363-2371, 2014 | 1523 | 2014 |
| 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer D Farge, C Frere, JM Connors, C Ay, AA Khorana, A Munoz, B Brenner, ... The Lancet Oncology 20 (10), e566-e581, 2019 | 444 | 2019 |
| American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19 A Cuker, EK Tseng, R Nieuwlaat, P Angchaisuksiri, C Blair, K Dane, ... Blood advances 5 (3), 872-888, 2021 | 437 | 2021 |
| Integration of genetic, clinical, and INR data to refine warfarin dosing P Lenzini, M Wadelius, S Kimmel, JL Anderson, AL Jorgensen, ... Clinical Pharmacology & Therapeutics 87 (5), 572-578, 2010 | 264 | 2010 |
| Safety and pharmacokinetics of anti‐TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial P Chowdary, S Lethagen, U Friedrich, B Brand, C Hay, FA Karim, ... Journal of Thrombosis and Haemostasis 13 (5), 743-754, 2015 | 240 | 2015 |
| Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, Prothrombin 20210A and Methylenetethraydrofolate reductase C677T: a meta-analysis … B Simone, V De Stefano, E Leoncini, J Zacho, I Martinelli, J Emmerich, ... European journal of epidemiology 28, 621-647, 2013 | 238 | 2013 |
| Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial PW Collins, G Young, K Knobe, FA Karim, P Angchaisuksiri, C Banner, ... Blood, The Journal of the American Society of Hematology 124 (26), 3880-3886, 2014 | 196 | 2014 |
| Pulmonary arterial hypertension in previously splenectomized patients with β-thalassemic disorders V Atichartakarn, K Likittanasombat, S Chuncharunee, P Chandanamattha, ... International journal of hematology 78, 139-145, 2003 | 184 | 2003 |
| 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19 D Farge, C Frere, JM Connors, AA Khorana, A Kakkar, C Ay, A Muñoz, ... The Lancet Oncology 23 (7), e334-e347, 2022 | 172 | 2022 |
| Relationship between hypercoagulable state and erythrocyte phosphatidylserine exposure in splenectomized haemoglobin E/β‐thalassaemic patients V Atichartakarn, P Angchaisuksiri, K Aryurachai, S Onpun, ... British journal of haematology 118 (3), 893-898, 2002 | 171 | 2002 |
| Quality of vitamin K antagonist control and 1-year outcomes in patients with atrial fibrillation: a global perspective from the GARFIELD-AF registry S Haas, H Ten Cate, G Accetta, P Angchaisuksiri, JP Bassand, AJ Camm, ... PloS one 11 (10), e0164076, 2016 | 169 | 2016 |
| Global public awareness of venous thromboembolism AM Wendelboe, M McCumber, EM Hylek, H Buller, JI Weitz, G Raskob, ... Journal of Thrombosis and Haemostasis 13 (8), 1365-1371, 2015 | 166 | 2015 |
| Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial GE Raskob, N van Es, A Segers, P Angchaisuksiri, D Oh, Z Boda, ... The Lancet Haematology 3 (8), e379-e387, 2016 | 162 | 2016 |
| American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic … A Cuker, EK Tseng, R Nieuwlaat, P Angchaisuksiri, C Blair, K Dane, ... Blood advances 6 (17), 4915-4923, 2022 | 146 | 2022 |
| Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results AD Shapiro, P Angchaisuksiri, J Astermark, G Benson, G Castaman, ... Blood, The Journal of the American Society of Hematology 134 (22), 1973-1982, 2019 | 144 | 2019 |
| A proposal for staging COVID‐19 coagulopathy J Thachil, M Cushman, A Srivastava, P Angchaisuksiri Research and practice in thrombosis and haemostasis 4 (5), 731-736, 2020 | 120 | 2020 |
| Incidence of thromboembolism in patients with COVID-19: a systematic review and meta-analysis K Boonyawat, P Chantrathammachart, P Numthavaj, N Nanthatanti, ... Thrombosis journal 18, 1-12, 2020 | 109 | 2020 |
| In vivo platelet activation and hyperaggregation in hemoglobin E/β-thalassemia: a consequence of splenectomy V Atichartakarn, P Angchaisuksiri, K Aryurachai, S Chuncharunee, ... International journal of hematology 77, 299-303, 2003 | 107 | 2003 |
| Characteristics and management of patients with venous thromboembolism: the GARFIELD-VTE registry W Ageno, S Haas, JI Weitz, SZ Goldhaber, AGG Turpie, S Goto, ... Thrombosis and haemostasis 119 (02), 319-327, 2019 | 93 | 2019 |
| Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy BD Horne, PA Lenzini, M Wadelius, AL Jorgensen, SE Kimmel, PM Ridker, ... Thrombosis and haemostasis 107 (02), 232-240, 2012 | 89 | 2012 |
